Hoth Therapeutics, Inc.
Hoth Therapeutics is dedicated to developing innovative, impactful, and ground-breaking treatments to improve patient quality of life. They focus on early-stage pharmaceutical research and development, collaborating with scientists, clinicians, and key opinion leaders to seek out and investigate promising medications. Their mission is driven by a patient-centric approach, aiming to create breakthroughs and diversify treatment options across various therapeutic areas including oncology, neurology, inflammatory diseases, dermatology, and medical devices.
Industries
Nr. of Employees
small (1-50)
Hoth Therapeutics, Inc.
Not specified in the provided content.
Patents
Products
HT-001
A topical treatment aimed at reducing skin toxicities associated with EGFR inhibitor cancer therapy.
BioLexa
A topical lotion for treating eczema flares by targeting S. aureus colonization contributing to skin barrier dysfunction.
HT-KIT Injection
Targets proto-oncogene c-KIT for treating mast cell derived cancers and has received Orphan Designation.
HT-ALZ
An oral soluble film for Alzheimer’s disease treatment, leveraging existing safety data for expedited development.
HT-TBI
An injectable treatment for traumatic brain injury and ischemic stroke, focusing on emergency and non-clinic use.
HT-004
An Antisense oligonucleotide for treating IgE-mediated allergies and asthma, targeting FcεRIβ via alternative splicing.
HT-001
A topical treatment aimed at reducing skin toxicities associated with EGFR inhibitor cancer therapy.
BioLexa
A topical lotion for treating eczema flares by targeting S. aureus colonization contributing to skin barrier dysfunction.
HT-KIT Injection
Targets proto-oncogene c-KIT for treating mast cell derived cancers and has received Orphan Designation.
HT-ALZ
An oral soluble film for Alzheimer’s disease treatment, leveraging existing safety data for expedited development.
HT-TBI
An injectable treatment for traumatic brain injury and ischemic stroke, focusing on emergency and non-clinic use.
HT-004
An Antisense oligonucleotide for treating IgE-mediated allergies and asthma, targeting FcεRIβ via alternative splicing.
Services
Collaborative arrangements with academic groups, clinicians, and contract organizations to advance early-stage therapeutic candidates from bench to pre-clinical and early clinical stages.
Support for clinical trial activities and patient-facing programs including expanded access and compassionate use pathways.
Design and execution of pre-clinical studies including behavioral assessments in rodent models and application of in vivo analytical methods for protein kinetics.
Collaborative arrangements with academic groups, clinicians, and contract organizations to advance early-stage therapeutic candidates from bench to pre-clinical and early clinical stages.
Support for clinical trial activities and patient-facing programs including expanded access and compassionate use pathways.
Design and execution of pre-clinical studies including behavioral assessments in rodent models and application of in vivo analytical methods for protein kinetics.
Expertise Areas
- Early-stage drug development
- Pre-clinical pharmacology and animal models
- Translational research
- Neurodegenerative disease research
Key Technologies
- Micro-immunoelectrode (MIE) technology for in vivo protein measurement
- In vivo microdialysis
- Rodent behavioral assay platforms
- Electrochemical aerosol pathogen detection sensors